All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Does adding inotuzumab ozogamicin to frontline therapy improve survival outcomes for adults with B-ALL?

Jan 13, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub was pleased to speak to Nicholas Short, MD Anderson Cancer Center, Houston, US. We asked, Does adding inotuzumab ozogamicin to frontline therapy improve survival outcomes for adults with B-ALL?

Does adding inotuzumab ozogamicin to frontline therapy improve survival outcomes for adults with B-ALL?

Short begins by discussing the recent improvements in overall survival for patients with B-ALL following the introduction of inotuzumab ozogamicin, particularly in the relapsed/refractory setting. Short then outlines several combination treatments that include this anti-CD22 antibody-drug conjugate and their resulting long-term survival rates. The difference in response between older and younger adults is also discussed. Short concludes by looking to the future of combination and sequential therapies within standard treatment which could further improve outcomes and reduce the need of transplant in patients with ALL.